Subcutaneous immune globulin (SCIG)

Medical Letter on Drugs and Therapeutics

Volumn 49, Issue 1258, 2007, Pages 31-32

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG; VIVAGLOBIN;

AREA UNDER THE CURVE; CHILL; CLINICAL TRIAL; DRUG COST; DRUG FORMULATION; ERYTHEMA; FEVER; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; INJECTION SITE EDEMA; MYALGIA; NAUSEA AND VOMITING; SHORT SURVEY; ADULT; ARTICLE; CHILD; METHODOLOGY; PASSIVE IMMUNIZATION; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; CHILD; CLINICAL TRIALS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; INJECTIONS, SUBCUTANEOUS;

EID: 34247167028     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (6)

1. Intravenous immunoglobulin (IVIG). Med Lett Drugs Ther 2006; 48:101.
2. A Gardulf et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies - a prospective, multi-national study. J Clin Immunol 2006; 26:177.
3. HD Ochs et al. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006; 26:265.
4. HM Chapel et al. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000; 20:94.
5. Price according to the manufacturer of Vivaglobin.
6. Price according to Medical Letter consultants.